OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
The treatment was effective across all weight groups.
Looking at the data from ORION-9, ORION-10, and ORION-11 trials show inclisiran is effective in lowering low-density lipoprotein cholesterol (LDL-C), across patients of all body weight.
The ad-hoc analysis, which was presented during the 2021 American Heart Association (AHA) Scientific Sessions, show twice-yearly treatment resulted in effective and sustained reduction of approximately 50% in LDL-C at week 17 when used in addition to other lipid lowering therapies.
In an interview with HCPLive®, Lawrence A. Leiter, MD, Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, explained the results of the ad-hoc study and why it is important to find treatments for patients across all ranges of body mass indexes (BMI).
Patients with high BMI or obese patients are at an elevated risk of bad cholesterol, a risk factor that results in significantly increased risk for a cardiovascular event.
Leiter said often treatments have the pharmacology altered in overweight or obese patients, but this treatment this does not seem to be the case.
He also said the medication was well-tolerated across all patient groups.